Percp cy5.5 conjugated anti cd56

Fc receptors were blocked with Fcγ blocker (BioLegend, San Diego, CA, USA), and the surface markers were stained with BV450-conjugated anti-CD3 (BioLegend, clone:UCHT1), FITC-conjugated anti-CD19 (BioLegend, clone: HIB19), APC/Cy7-conjugated anti-CD20 (BioLegend, clone: 2H7), PE-conjugated anti-CD14 (BioLegend, clone: ΦM P9), PE-conjugated anti-CD11c (BioLegend, clone: B-ly6), PerCP/Cy5.5-conjugated anti-CD56 (BioLegend, clone: B159), FITC-conjugated anti-CD16 (BioLegend, clone:3G8), PE-conjugated anti-CD123 (BioLegend, clone: 6H6), and APC/Cy7-conjugated anti-CD4 (BioLegend, clone: RPA-T4). After fixing and permeabilization, IGBP1 was stained with Alexa 647-conjugated anti-IGBP1 (Novus Biologicals, Centennial, CO, USA).

The anti-VSIG4 antibody (Cat# bs-0479R, RRID: AB_10855328) and anti-TGF-beta antibody (Cat# bs-0086R, RRID: AB_10856457) were obtained from Bioss (China). The anti-GAPDH antibody (Cat# 10494-1-AP, RRID: AB_2263076) was obtained from Proteintech (China) and HRP-conjugated Affinipure goat anti-rabbit immunoglobulin G (IgG) (H + L) antibody (Cat# SA00001-2, RRID: AB_2722564) were obtained from Proteintech (China). The following human-specific mAbs were used: Pe-cy7-conjugated anti-CD14 (Cat# 25–0149-42, RRID: AB_1582276) and allophycocyanin APC-conjugated anti-VSIG4 (Cat# 17–5757-41, RRID: AB_2637396) were obtained from Thermo Fisher Scientific (USA). Fluorescein isothiocyanate (FITC)-conjugated anti-CD3 (Cat# 300406, RRID: AB_314060), PerCP/Cy5.5 conjugated anti-CD56 (Cat# 318322, RRID: AB_893389), and FITC-conjugated anti-line (Cat# 348801, RRID: AB_ 10612570) PerCP/Cy5.5 anti-HLA-DR (Cat# 307630, RRID: AB_893575) were obtained from Biolegend (USA).